Share Article
- Product Sales of
- Non-GAAP EPS of
- Revised 2015 Net Product Sales Guidance -
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| (In millions, except per share amounts) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Product sales | $ | 8,211 | $ | 5,968 | $ | 23,742 | $ | 17,252 | ||||
| Royalty, contract and other revenues | 84 | 74 | 391 | 324 | ||||||||
| Total revenues | $ | 8,295 | $ | 6,042 | $ | 24,133 | $ | 17,576 | ||||
| Net income attributable to Gilead | $ | 4,600 | $ | 2,731 | $ | 13,425 | $ | 8,614 | ||||
| Non-GAAP net income attributable to Gilead | $ | 4,836 | $ | 3,014 | $ | 14,285 | $ | 9,431 | ||||
| Diluted EPS | $ | 3.06 | $ | 1.67 | $ | 8.73 | $ | 5.18 | ||||
| Non-GAAP diluted EPS | $ | 3.22 | $ | 1.84 | $ | 9.29 | $ | 5.68 | ||||
Product Sales
Total product sales for the third quarter of 2015 were
Antiviral Product Sales
Antiviral product sales were
Other Product Sales
Other product sales, which include Letairis® (ambrisentan),
Ranexa® (ranolazine) and AmBisome® (amphotericin B
liposome for injection), were
Operating Expenses
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| (In millions) | 2015 | 2014 | 2015 | 2014 | ||||||||
| Non-GAAP research and development expenses (R&D) | $ | 713 | $ | 586 | $ | 2,066 | $ | 1,686 | ||||
| Non-GAAP selling, general and administrative expenses (SG&A) | $ | 850 | $ | 888 | $ | 2,211 | $ | 1,958 | ||||
Note:Non-GAAP R&D and SG&A expenses exclude amounts related to acquisition, restructuring, stock-based compensation and other.
During the third quarter of 2015, compared to the same period in 2014:
- Non-GAAP research and development expenses increased primarily due to the progression of Gilead's clinical studies.
- Non-GAAP selling, general and administrative expenses decreased primarily due to a cumulative catch-up of the branded prescription drug fee recorded in the same period in 2014, partially offset by higher costs to support Gilead's growth and the geographic expansion in its business.
Cash,
As of
Revised 2015 Full Year Guidance
Gilead updated its full year 2015 guidance as follows:
| (In millions, except percentages and per share amounts) | InitiallyProvidedFebruary 3, 2015 | UpdatedApril 30, 2015 | UpdatedJuly 28, 2015 | UpdatedOctober 27, 2015 | |||||||
| Net Product Sales | $26,000 - $27,000 | $28,000 - $29,000 | $29,000 - $30,000 | $30,000 - $31,000 | |||||||
| Non-GAAP* | |||||||||||
| Product Gross Margin | 87% - 90% | 87% - 90% | 88% - 90% | 88% - 90% | |||||||
| R&D expenses | $3,000 - $3,300 | $3,000 - $3,300 | $2,800 - $3,000 | $2,800 - $3,000 | |||||||
| SG&A expenses | $3,000 - $3,300 | $3,000 - $3,300 | $3,000 - $3,200 | $3,000 - $3,200 | |||||||
| Effective Tax Rate | 18.0% - 20.0% | 18.0% - 20.0% | 17.0% - 18.0% | 17.0% - 18.0% | |||||||
| Diluted EPS Impact of Acquisition-Related, Restructuring, Stock-Based Compensation Expenses and Other | $0.82 - $0.87 | $0.82 - $0.87 | $0.82 - $0.87 | $0.82 - $0.87 | |||||||
| * Non-GAAP product gross margin, R&D and SG&A expenses and effective tax rate exclude amounts related to acquisition, restructuring, stock-based compensation and other. | |||||||||||
Product & Pipeline Updates Announced by
Antiviral Program
- Announced positive topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 HCV infection. In the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies, patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and 28 percent had failed prior treatments. In the ASTRAL-4 study, patients with decompensated cirrhosis (Child-Pugh class B) received 12 weeks of SOF/VEL with or without ribavirin, or 24 weeks of SOF/VEL.
-
Announced that the
Japanese Ministry of Health, Labour and Welfare approved Harvoni, the first once-daily single tablet regimen (STR) for the treatment of chronic hepatitis C genotype 1 infection in adults. InJapan , Harvoni is indicated for the suppression of viremia in patients with genotype 1 HCV infection with or without compensated cirrhosis, with a treatment duration of 12 weeks. -
Announced that the company submitted a New Drug Application (NDA) to
the
U.S. Food and Drug Administration (FDA ) for an investigational, once-daily STR that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies ofJohnson & Johnson , for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. -
Announced that the company’s Marketing Authorization Application (MAA)
for R/F/TAF was fully validated and under evaluation by the
European Medicines Agency (EMA). The data included in the application support the use of R/F/TAF for the treatment of HIV-1 infection in adults and pediatric patients 12 years and older. -
Announced that the
Committee for Medicinal Products for Human Use , the scientific committee of the EMA, adopted a positive opinion on the company’s MAA for E/C/F/TAF onSeptember 25, 2015 . - Announced a Phase 3 study of F/TAF for the treatment of HIV-1 infection met its primary objective. The ongoing study was designed to explore the efficacy and safety of F/TAF-based regimens among virologically suppressed adult patients switching from HIV treatment regimens containing emtricitabine/tenofovir disoproxil fumarate. At week 48, the F/TAF-based regimens and the TDF-based regimens achieved similar rates of virologic suppression based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL.
-
Announced positive results from a Phase 3 clinical study of E/C/F/TAF
among virologically suppressed adult patients switching from
TDF-containing regimens. The study met its primary endpoint by
demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens
at week 48. The study also demonstrated statistical superiority among
patients with HIV-1 RNA levels less than 50 copies/mL at week 48 and
statistically significant improvements in bone and renal laboratory
parameters. These data were presented at the 8th
IAS Conference on HIV Pathogenesis , Treatment & Prevention.
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7 and 8.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2015 financial results; Gilead's ability to
sustain growth in revenues for its antiviral and other programs;
availability of funding for state AIDS Drug Assistance Programs (ADAPs);
continued fluctuations in ADAP purchases driven by federal and state
grant cycles which may not mirror patient demand and may cause
fluctuations in Gilead's earnings; the possibility of unfavorable
results from clinical trials involving sofosbuvir-containing products,
including fixed dose combination of SOF/VEL; Gilead's ability to
initiate clinical trials in its currently anticipated timeframes; the
levels of inventory held by wholesalers and retailers which may cause
fluctuations in Gilead's earnings; Gilead's ability to submit new drug
applications for new product candidates in the timelines currently
anticipated; Gilead's ability to receive regulatory approvals in a
timely manner or at all, for new and current products, including
E/C/F/TAF, F/TAF and R/F/TAF; Gilead's ability to successfully
commercialize its products; the risk that physicians and patients may
not see advantages of these products over other therapies and may
therefore be reluctant to prescribe the products; the risk that
estimates of patients with HCV or anticipated patient demand may not be
accurate; the risk that private and public payers may be reluctant to
provide, or continue to provide, coverage or reimbursement for new
products, including Sovaldi and Harvoni; Gilead's ability to
successfully develop its oncology, inflammation, cardiovascular and
respiratory programs; safety and efficacy data from clinical studies may
not warrant further development of Gilead's product candidates,
including the fixed dose regimen of SOF/VEL; the potential for
additional austerity measures in European countries that may increase
the amount of discount required on Gilead's products; Gilead's ability
to complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; Gilead’s ability to pay
dividends under its dividend program and the risk that its Board of
Directors may reduce the amount of the dividend; fluctuations in the
foreign exchange rate of the U.S. dollar that may cause an unfavorable
foreign currency exchange impact on Gilead's future revenues and pre-tax
earnings; and other risks identified from time to time in Gilead's
reports filed with the
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 8,211 | $ | 5,968 | $ | 23,742 | $ | 17,252 | ||||||||
| Royalty, contract and other revenues | 84 | 74 | 391 | 324 | ||||||||||||
| Total revenues | 8,295 | 6,042 | 24,133 | 17,576 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 1,064 | 987 | 2,944 | 2,725 | ||||||||||||
| Research and development expenses | 743 | 630 | 2,257 | 1,809 | ||||||||||||
| Selling, general and administrative expenses | 903 | 945 | 2,360 | 2,107 | ||||||||||||
| Total costs and expenses | 2,710 | 2,562 | 7,561 | 6,641 | ||||||||||||
| Income from operations | 5,585 | 3,480 | 16,572 | 10,935 | ||||||||||||
| Interest expense | (165 | ) | (104 | ) | (458 | ) | (282 | ) | ||||||||
| Other income (expense), net | 52 | (5 | ) | 108 | (27 | ) | ||||||||||
| Income before provision for income taxes | 5,472 | 3,371 | 16,222 | 10,626 | ||||||||||||
| Provision for income taxes | 880 | 647 | 2,801 | 2,029 | ||||||||||||
| Net income | 4,592 | 2,724 | 13,421 | 8,597 | ||||||||||||
| Net loss attributable to noncontrolling interest | (8 | ) | (7 | ) | (4 | ) | (17 | ) | ||||||||
| Net income attributable to Gilead | $ | 4,600 | $ | 2,731 | $ | 13,425 | $ | 8,614 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 3.14 | $ | 1.80 | $ | 9.11 | $ | 5.64 | ||||||||
| Shares used in per share calculation - basic | 1,463 | 1,514 | 1,474 | 1,528 | ||||||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 3.06 | $ | 1.67 | $ | 8.73 | $ | 5.18 | ||||||||
| Shares used in per share calculation - diluted | 1,503 | 1,637 | 1,538 | 1,662 | ||||||||||||
| Cash dividends declared per share | $ | 0.43 | $ | — | $ | 0.86 | $ | — | ||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 1,064 | $ | 987 | $ | 2,944 | $ | 2,725 | ||||||||
| Stock-based compensation expenses | (3 | ) | (3 | ) | (9 | ) | (8 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (207 | ) | (201 | ) | (620 | ) | (600 | ) | ||||||||
| Other(1) | 2 | — | 3 | — | ||||||||||||
| Non-GAAP cost of goods sold | $ | 856 | $ | 783 | $ | 2,318 | $ | 2,117 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 87.0 | % | 83.5 | % | 87.6 | % | 84.2 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.5 | % | 3.4 | % | 2.6 | % | 3.5 | % | ||||||||
| Non-GAAP product gross margin(2) | 89.6 | % | 86.9 | % | 90.2 | % | 87.7 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 743 | $ | 630 | $ | 2,257 | $ | 1,809 | ||||||||
| Stock-based compensation expenses | (44 | ) | (40 | ) | (128 | ) | (111 | ) | ||||||||
| Acquisition related expenses | — | — | (66 | ) | — | |||||||||||
| Other(1) | 14 | (4 | ) | 3 | (12 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 713 | $ | 586 | $ | 2,066 | $ | 1,686 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 903 | $ | 945 | $ | 2,360 | $ | 2,107 | ||||||||
| Stock-based compensation expenses | (50 | ) | (56 | ) | (148 | ) | (146 | ) | ||||||||
| Restructuring expenses | — | — | 2 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | — | (1 | ) | — | (3 | ) | ||||||||||
| Other(1) | (3 | ) | — | (3 | ) | — | ||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 850 | $ | 888 | $ | 2,211 | $ | 1,958 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 67.3 | % | 57.6 | % | 68.7 | % | 62.2 | % | ||||||||
| Stock-based compensation expenses | 1.2 | % | 1.6 | % | 1.2 | % | 1.5 | % | ||||||||
| Acquisition related expenses | — | % | — | % | 0.3 | % | — | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 2.5 | % | 3.3 | % | 2.6 | % | 3.4 | % | ||||||||
| Other(1) | (0.2 | )% | 0.1 | % | — | % | 0.1 | % | ||||||||
| Non-GAAP operating margin(2) | 70.8 | % | 62.6 | % | 72.7 | % | 67.2 | % | ||||||||
| Other income (expense) reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | 52 | $ | (5 | ) | $ | 108 | $ | (27 | ) | ||||||
| Other(1) | 1 | — | 1 | (2 | ) | |||||||||||
| Non-GAAP other income (expense), net | $ | 53 | $ | (5 | ) | $ | 109 | $ | (29 | ) | ||||||
| Notes: | ||||||||||||||||
| (1) Amounts related to consolidation of a contract manufacturer, contingent consideration and/or other individually insignificant amounts | ||||||||||||||||
| (2) Amounts may not sum due to rounding | ||||||||||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 16.1 | % | 19.2 | % | 17.3 | % | 19.1 | % | ||||||||
| Stock-based compensation expenses | 0.4 | % | — | % | 0.1 | % | — | % | ||||||||
| Acquisition related-amortization of purchased intangibles | (0.2 | )% | (1.0 | )% | (0.4 | )% | (0.9 | )% | ||||||||
| Non-GAAP effective tax rate(1) | 16.3 | % | 18.2 | % | 17.0 | % | 18.2 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 4,600 | $ | 2,731 | $ | 13,425 | $ | 8,614 | ||||||||
| Stock-based compensation expenses | 44 | 81 | 184 | 217 | ||||||||||||
| Restructuring expenses | — | — | (2 | ) | — | |||||||||||
| Acquisition related expenses | — | — | 66 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 202 | 198 | 605 | 589 | ||||||||||||
| Other(2) | (10 | ) | 4 | 7 | 11 | |||||||||||
| Non-GAAP net income attributable to Gilead | $ | 4,836 | $ | 3,014 | $ | 14,285 | $ | 9,431 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 3.06 | $ | 1.67 | $ | 8.73 | $ | 5.18 | ||||||||
| Stock-based compensation expenses | 0.03 | 0.05 | 0.12 | 0.13 | ||||||||||||
| Acquisition related expenses | — | — | 0.04 | — | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 0.13 | 0.12 | 0.39 | 0.35 | ||||||||||||
| Other(2) | (0.01 | ) | — | 0.01 | 0.01 | |||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 3.22 | $ | 1.84 | $ | 9.29 | $ | 5.68 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,503 | 1,637 | 1,538 | 1,662 | ||||||||||||
| Share impact of current stock-based compensation rules | (1 | ) | (1 | ) | (1 | ) | (1 | ) | ||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,502 | 1,636 | 1,537 | 1,661 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 208 | $ | 204 | $ | 626 | $ | 608 | ||||||||
| Research and development expenses adjustments | 30 | 44 | 191 | 123 | ||||||||||||
| Selling, general and administrative expenses adjustments | 53 | 57 | 149 | 149 | ||||||||||||
| Other income (expense) adjustments | 1 | — | 1 | (2 | ) | |||||||||||
| Total non-GAAP adjustments before tax | 292 | 305 | 967 | 878 | ||||||||||||
| Income tax effect | (58 | ) | (23 | ) | (116 | ) | (61 | ) | ||||||||
| Other(2) | 2 | — | 9 | — | ||||||||||||
| Total non-GAAP adjustments after tax attributable to Gilead | $ | 236 | $ | 282 | $ | 860 | $ | 817 | ||||||||
| Notes: | ||||||||||||||||
| (1) Amounts may not sum due to rounding | ||||||||||||||||
| (2) Amounts related to consolidation of a contract manufacturer, contingent consideration and/or other individually insignificant amounts | ||||||||||||||||
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) | ||||||||
| September 30, | December 31, | |||||||
| 2015 | 2014(1) | |||||||
| Cash, cash equivalents and marketable securities | $ | 25,114 | $ | 11,726 | ||||
| Accounts receivable, net | 6,105 | 4,635 | ||||||
| Inventories | 1,988 | 1,386 | ||||||
| Property, plant and equipment, net | 2,143 | 1,674 | ||||||
| Intangible assets, net | 10,454 | 11,073 | ||||||
| Goodwill | 1,172 | 1,172 | ||||||
| Other assets | 3,661 | 2,998 | ||||||
| Total assets | $ | 50,637 | $ | 34,664 | ||||
| Current liabilities | $ | 9,360 | $ | 5,761 | ||||
| Long-term liabilities | 23,329 | 13,069 | ||||||
| Equity component of currently redeemable convertible notes | 4 | 15 | ||||||
| Stockholders’ equity(2) | 17,944 | 15,819 | ||||||
| Total liabilities and stockholders’ equity | $ | 50,637 | $ | 34,664 | ||||
| Notes: | ||||||||
(1) Derived from the audited consolidated financial statements as of December 31, 2014. | ||||||||
(2) As of September 30, 2015, there were 1,449 million shares of common stock issued and outstanding. | ||||||||
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2015 | 2014 | 2015 | 2014 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Harvoni – U.S. | $ | 2,541 | $ | — | $ | 8,383 | $ | — | |||||||
| Harvoni – Europe | 532 | 20 | 1,632 | 20 | |||||||||||
| Harvoni – Other International | 259 | — | 504 | — | |||||||||||
| 3,332 | 20 | 10,519 | 20 | ||||||||||||
| Sovaldi – U.S. | 692 | 2,200 | 1,728 | 7,329 | |||||||||||
| Sovaldi – Europe | 337 | 523 | 1,342 | 1,087 | |||||||||||
| Sovaldi – Other International | 437 | 73 | 659 | 135 | |||||||||||
| 1,466 | 2,796 | 3,729 | 8,551 | ||||||||||||
| Truvada – U.S. | 561 | 472 | 1,470 | 1,239 | |||||||||||
| Truvada – Europe | 268 | 327 | 846 | 988 | |||||||||||
| Truvada – Other International | 74 | 78 | 207 | 216 | |||||||||||
| 903 | 877 | 2,523 | 2,443 | ||||||||||||
| Atripla – U.S. | 597 | 621 | 1,640 | 1,689 | |||||||||||
| Atripla – Europe | 161 | 223 | 533 | 694 | |||||||||||
| Atripla – Other International | 60 | 51 | 161 | 162 | |||||||||||
| 818 | 895 | 2,334 | 2,545 | ||||||||||||
| Stribild – U.S. | 422 | 278 | 1,068 | 695 | |||||||||||
| Stribild – Europe | 73 | 38 | 199 | 93 | |||||||||||
| Stribild – Other International | 16 | 11 | 47 | 24 | |||||||||||
| 511 | 327 | 1,314 | 812 | ||||||||||||
| Complera / Eviplera – U.S. | 210 | 183 | 580 | 467 | |||||||||||
| Complera / Eviplera – Europe | 137 | 134 | 427 | 375 | |||||||||||
| Complera / Eviplera – Other International | 13 | 13 | 40 | 38 | |||||||||||
| 360 | 330 | 1,047 | 880 | ||||||||||||
| Viread – U.S. | 151 | 122 | 385 | 320 | |||||||||||
| Viread – Europe | 76 | 87 | 233 | 259 | |||||||||||
| Viread – Other International | 70 | 66 | 184 | 168 | |||||||||||
| 297 | 275 | 802 | 747 | ||||||||||||
| Other Antiviral – U.S. | 8 | 14 | 30 | 34 | |||||||||||
| Other Antiviral – Europe | 6 | 9 | 20 | 28 | |||||||||||
| Other Antiviral – Other International | 1 | 1 | 3 | 5 | |||||||||||
| 15 | 24 | 53 | 67 | ||||||||||||
| Total antiviral products – U.S. | 5,182 | 3,890 | 15,284 | 11,773 | |||||||||||
| Total antiviral products – Europe | 1,590 | 1,361 | 5,232 | 3,544 | |||||||||||
| Total antiviral products – Other International | 930 | 293 | 1,805 | 748 | |||||||||||
| 7,702 | 5,544 | 22,321 | 16,065 | ||||||||||||
| Other products: | |||||||||||||||
| Letairis | 181 | 146 | 508 | 414 | |||||||||||
| Ranexa | 161 | 132 | 419 | 366 | |||||||||||
| AmBisome | 88 | 98 | 276 | 284 | |||||||||||
| Zydelig | 36 | 6 | 92 | 6 | |||||||||||
| Other | 43 | 42 | 126 | 117 | |||||||||||
| 509 | 424 | 1,421 | 1,187 | ||||||||||||
| Total product sales | $ | 8,211 | $ | 5,968 | $ | 23,742 | $ | 17,252 | |||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20151027006687/en/
Source:
Gilead Sciences, Inc.Robin Washington, 650-522-5688 (Investors)Patrick O'Brien, 650-522-1936 (Investors)Amy Flood, 650-522-5643 (Media)
Other News
Some of the content on this page is not intended for users outside the U.S.